Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Langenbeck's Archives of Surgery
Erschienen in: Langenbeck's Archives of Surgery 6/2006

01.11.2006 | New Surgical Horizons

Cigarette smoking: cancer risks, carcinogens, and mechanisms

verfasst von: Stephen S. Hecht

Erschienen in: Langenbeck's Archives of Surgery | Ausgabe 6/2006

Einloggen, um Zugang zu erhalten

Abstract

Background

Cigarette smoking causes about 30% of all cancer mortality in developed countries. Although smoking is decreasing in developed countries, it is increasing in some developing countries.

Discussion

Cigarette smoke contains over 60 well established carcinogens. There are strong links between some of these carcinogens and various types of smoking-induced cancers. Mechanisms by which cigarette smoke carcinogens cause cancer are well established and are discussed here.

Conclusions

A great deal is known about cigarette smoke carcinogens and the mechanisms by which they cause cancer. It is hoped that this will provide new insights for the prevention and cure of tobacco-induced cancer.
Literatur
1.
Mackay J, Eriksen M (2002) The tobacco atlas. World Health Organization, Geneva, pp 24–27
2.
International Agency for Research on Cancer (2004) Tobacco smoke and involuntary smoking. IARC monographs on the evaluation of carcinogenic risks to humans, vol 83. IARC, Lyon, FR, pp 53–119
3.
International Agency for Research on Cancer (2004) Tobacco smoke and involuntary smoking. IARC monographs on the evaluation of carcinogenic risks to humans, vol 83. IARC, Lyon, FR, pp 1179–1187
4.
Centers for Disease Control (2005) Cigarette smoking among adults—United States, 2004. MMWR 54:1121–1124
5.
Wynder EL, Graham EA (1950) Tobacco smoking as a possible etiologic factor in bronchiogenic carcinoma. A study of six hundred and eighty-four proved cases. JAMA 143:329–336
6.
Doll R, Hill AB (1950) Smoking and carcinoma of the lung. A preliminary report. Br Med J ii:739–748CrossRef
7.
U.S. Department of Health and Human Services (2004) The health consequences of smoking: a report of the surgeon general. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control, Center for Health Promotion and Education, Office on Smoking and Health, Rockville, MD
8.
U.S.Department of Health and Human Services (2006) The health consequences of involuntary exposure to tobacco smoke: a report of the surgeon general. U.S. Dept. of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, Washington, DC, p 709
9.
10.
International Agency for Research on Cancer (1983) Polynuclear aromatic compounds, part 1, chemical, environmental, and experimental data. IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans, vol 32. IARC, Lyon, FR, pp 33–91
11.
Dipple A, Moschel RC, Bigger CAH (1984) Polynuclear aromatic hydrocarbons. In: Searle CE (ed) Chemical carcinogens, second edition, ACS monograph 182, vol 1. American Chemical Society, Washington, D.C., pp 41–163
12.
Straif K, Baan R, Grosse Y, Secretan B, El Ghissassi F, Cogliano V (2005) Carcinogenicity of polycyclic aromatic hydrocarbons. Lancet Oncol 6:931–932PubMedCrossRef
13.
Preussmann R,Stewart BW (1984) N-Nitroso carcinogens. In: Searle CE (ed) Chemical carcinogens, second edition, ACS monograph 182, vol 2. American Chemical Society, Washington, DC, pp 643–828
14.
Hecht SS, Hoffmann D (1988) Tobacco-specific nitrosamines, an important group of carcinogens in tobacco and tobacco smoke. Carcinogenesis 9:875–884PubMed
15.
Hecht SS (1998) Biochemistry, biology, and carcinogenicity of tobacco-specific N-nitrosamines. Chem Res Toxicol 11:559–603PubMedCrossRef
16.
International Agency for Research on Cancer (2006) Smokeless tobacco and tobacco-specific nitrosamines. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, vol 89. IARC, Lyon, FR (in press)
17.
Luch A (2005) Nature and nurture—lessons from chemical carcinogenesis. Nat Rev Cancer 5:113–125PubMedCrossRef
18.
Sugimura T (1995) History, present and future, of heterocyclic amines, cooked food mutagens. Princess Takamatsu Symp 23:214–231PubMed
19.
International Agency for Research on Cancer (1995) Wood dust and formaldehyde. IARC monographs on the evaluation of carcinogenic risks to humans, vol 62. IARC, Lyon, FR, pp 217–362
20.
International Agency for Research on Cancer (1999) Re-evaluation of some organic chemicals, hydrazine and hydrogen peroxide (Part Two). IARC monographs on the evaluation of carcinogenic risks to humans, vol 71. IARC, Lyon, FR, pp 319–451
21.
International Agency for Research on Cancer (1993) Some naturally occurring substances: food items and constituents, heterocyclic aromatic amines and mycotoxins. IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans, vol 56. IARC, Lyon, FR, pp 115–134
22.
International Agency for Research on Cancer (1999) Re-evaluation of some organic chemicals, hydrazine and hydrogen peroxide (part one). IARC monographs on the evaluation of carcinogenic risks to humans, vol 71. IARC, Lyon, FR, pp 109–225
23.
International Agency for Research on Cancer (1982) Some industrial chemicals and dyestuffs. IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans, vol 29. IARC, Lyon, FR, pp 93–148
24.
International Agency for Research on Cancer (1979) Some monomers, plastics and synthetic elastomers, and acrolein. IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans, vol 19. IARC, Lyon, FR, pp 377–438
25.
International Agency for Research on Cancer (1994) Some industrial chemicals. IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans, vol 60. IARC, Lyon, FR, pp 73–159
26.
27.
Carmella SG, Chen M, Villalta PW, Gurney JG, Hatsukami DK, Hecht SS (2002) Ethylation and methylation of hemoglobin in smokers and non-smokers. Carcinogenesis 23:1903–1910PubMedCrossRef
28.
Singh R, Kaur B, Farmer PB (2005) Detection of DNA damage derived from a direct acting ethylating agent present in cigarette smoke by use of liquid chromatography-tandem mass spectrometry. Chem Res Toxicol 18:249–256PubMedCrossRef
29.
Hoffmann D, Schmeltz I, Hecht SS, Wynder EL (1978) Tobacco carcinogenesis. In: Gelboin H, Ts'o POP (eds) Polycyclic hydrocarbons and cancer. Academic, New York, pp 85–117
30.
Deutsch-Wenzel R, Brune H, Grimmer G (1983) Experimental studies in rat lungs on the carcinogenicity and dose–response relationships of eight frequently occurring environmental polycyclic aromatic hydrocarbons. J Natl Cancer Inst 71:539–544PubMed
31.
Pfeifer GP, Denissenko MF, Olivier M, Tretyakova N, Hecht SS, Hainaut P (2002) Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene 21:7435–7451PubMedCrossRef
32.
Boysen G, Hecht SS (2003) Analysis of DNA and protein adducts of benzo[a]pyrene in human tissues using structure-specific methods. Mutat Res 543:17–30PubMedCrossRef
33.
Phillips DH (2002) Smoking-related DNA and protein adducts in human tissues. Carcinogenesis 23:1979–2004PubMedCrossRef
34.
Liu Z, Muehlbauer KR, Schmeiser HH, Hergenhahn M, Belharazem D, Hollstein MC (2005) p53 mutations in benzo(a)pyrene-exposed human p53 knock-in murine fibroblasts correlate with p53 mutations in human lung tumors. Cancer Res 65:2583–2587PubMedCrossRef
35.
Belinsky SA, Foley JF, White CM, Anderson MW, Maronpot RR (1990) Dose–response relationship between O 6-methylguanine formation in Clara cells and induction of pulmonary neoplasia in the rat by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Cancer Res 50:3772–3780PubMed
36.
Hecht SS (2002) Human urinary carcinogen metabolites: biomarkers for investigating tobacco and cancer. Carcinogenesis 23:907–922PubMedCrossRef
37.
Shapiro JA, Jacobs EJ, Thun MJ (2000) Cigar smoking in men and risk of death from tobacco-related cancers. J Natl Cancer Inst 92:333–337PubMedCrossRef
38.
Boffetta P, Pershagen G, Jockel KH, Forastiere F, Gaborieau V, Heinrich J, Jahn I, Kreuzer M, Merletti F, Nyberg F, Rosch F, Simonato L (1999) Cigar and pipe smoking and lung cancer risk: a multicenter study from Europe. J Natl Cancer Inst 91:697–701PubMedCrossRef
39.
40.
Hoffmann D, Hoffmann I, El Bayoumy K (2001) The less harmful cigarette: a controversial issue. A tribute to Ernst L. Wynder. Chem Res Toxicol 14:767–790PubMedCrossRef
41.
International Agency for Research on Cancer (1986) Tobacco smoking. IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans, vol 38. IARC, Lyon, FR, pp 37–385
42.
Hoffmann D, Hecht SS (1990) Advances in tobacco carcinogenesis. In: Cooper CS, Grover PL (eds) Handbook of experimental pharmacology. Springer, Berlin Heidelberg New York, pp 63–102
43.
Lijinsky W (1992) Chemistry and biology Of N-nitroso compounds. Cambridge University Press, Cambridge, England
44.
Hecht SS, Hoffmann D (1989) The relevance of tobacco-specific nitrosamines to human cancer. Cancer Surv 8:273–294PubMed
45.
International Agency for Research on Cancer (1995) Dry cleaning, some chlorinated solvents and other industrial chemicals. IARC monographs on the evaluation of carcinogenic risks to humans, vol 63. IARC, Lyon, France, pp 393–407
46.
Prokopczyk B, Leder G, Trushin N, Cunningham AJ, Akerkar S, Pittman B, Ramadani M, Straeter J, Beger HG, Henne-Bruns D, El Bayoumy K (2005) 4-Hydroxy-1-(3-pyridyl)-1-butanone, an indicator for 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced DNA damage, is not detected in human pancreatic tissue. Cancer Epidemiol Biomarkers Prev 14:540–541PubMedCrossRef
47.
Rivenson A, Hoffmann D, Prokopczyk B, Amin S, Hecht SS (1988) Induction of lung and exocrine pancreas tumors in F344 rats by tobacco-specific and Areca-derived N-nitrosamines. Cancer Res 48:6912–6917PubMed
48.
Prokopczyk B, Hoffmann D, Bologna M, Cunningham AJ, Trushin N, Akerkar S, Boyiri T, Amin S, Desai D, Colosimo S, Pittman B, Leder G, Ramadani M, Henne-Bruns D, Beger HG, El Bayoumy K (2002) Identification of tobacco-derived compounds in human pancreatic juice. Chem Res Toxicol 15:677–685PubMedCrossRef
49.
Prokopczyk B, Trushin N, Leszczynska J, Waggoner SE, El Bayoumy K (2001) Human cervical tissue metabolizes the tobacco-specific nitrosamine, 4- (methylnitrosamino)-1-(3-pyridyl)-1-butanone, via alpha-hydroxylation and carbonyl reduction pathways. Carcinogenesis 22:107–114PubMedCrossRef
50.
Melikian AA, Sun P, Prokopczyk B, El Bayoumy K, Hoffmann D, Wang X, Waggoner S (1999) Identification of benzo[a]pyrene metabolites in cervical mucus and DNA adducts in cervical tissues in humans by gas chromatography-mass spectrometry. Cancer Lett 146:127–134PubMedCrossRef
51.
International Agency for Research on Cancer (1995) Human papillomaviruses. IARC monographs on the evaluation of carcinogenic risks to humans, vol 64. IARC, Lyon, FR, pp 35–378
52.
International Agency for Research on Cancer (1973) Some aromatic amines, hydrazine and related substances, N-nitroso compounds and miscellaneous alkylating agents. IARC monographs on the carcinogenic risk of chemicals to man, vol 4. IARC, Lyon, FR, pp 127–136
53.
Skipper PL, Tannenbaum SR (1990) Protein adducts in the molecular dosimetry of chemical carcinogens. Carcinogenesis 11:507–518PubMed
54.
Skipper PL, Peng X, SooHoo CK, Tannenbaum SR (1994) Protein adducts as biomarkers of human carcinogen exposure. Drug Metab Rev 26:111–124PubMed
55.
Landi MT, Zocchetti C, Bernucci I, Kadlubar FF, Tannenbaum S, Skipper P, Bartsch H, Malaveille C, Shields P, Caporaso NE, Vineis P (1996) Cytochrome P450 1A2: enzyme induction and genetic control in determining 4-aminobiphenyl-hemoglobin adduct levels. Cancer Epidemiol Biomark Prev 5:693–698
56.
Probst-Hensch NM, Bell DA, Watson MA, Skipper PL, Tannenbaum SR, Chan KK, Ross RK, Yu MC (2000) N-Acetyltransferase 2 phenotype but not NAT1*10 genotype affects aminobiphenyl–hemoglobin adduct levels. Cancer Epidemiol Biomark Prev 9:619–623
57.
Castelao JE, Yuan JM, Skipper PL, Tannenbaum SR, Gago-Dominguez M, Crowder JS, Ross RK, Yu MC (2001) Gender- and smoking-related bladder cancer risk. J Natl Cancer Inst 93:538–545PubMedCrossRef
58.
Pryor WA, Stone K, Zang LY, Bermudez E (1998) Fractionation of aqueous cigarette tar extracts: fractions that contain the tar radical cause DNA damage. Chem Res Toxicol 11:441–448PubMedCrossRef
59.
Guengerich FP (2001) Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem Res Toxicol 14:611–650PubMed
60.
Jalas J, Hecht SS, Murphy SE (2005) Cytochrome P450 2A enzymes as catalysts of metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), a tobacco-specific carcinogen. Chem Res Toxicol 18:95–110PubMedCrossRef
61.
Nebert DW, Dalton TP, Okey AB, Gonzalez FJ (2004) Role of aryl hydrocarbon receptor-mediated induction of the CYP1 enzymes in environmental toxicity and cancer. J Biol Chem 279:23847–23850PubMedCrossRef
62.
Armstrong RN (1997) Glutathione-S-transferases. In: Guengerich FP (ed) Comprehensive toxicology: biotransformation, vol 3. Elsevier Science, New York, pp 307–327
63.
Burchell B, McGurk K, Brierley CH, Clarke DJ (1997) UDP-glucuronosyltransferases. In: Guengerich FP (ed) Comprehensive toxicology: biotransformation, vol 3. Elsevier Science, New York, pp 401–436
64.
Vineis P, Veglia F, Benhamou S, Butkiewicz D, Cascorbi I, Clapper ML, Dolzan V, Haugen A, Hirvonen A, Ingelman-Sundberg M, Kihara M, Kiyohara C, Kremers P, Le Marchand L, Ohshima S, Pastorelli R, Rannug A, Romkes M, Schoket B, Shields P, Strange RC, Stucker I, Sugimura H, Garte S, Gaspari L, Taioli E (2003) CYP1A1 T3801 C polymorphism and lung cancer: a pooled analysis of 2451 cases and 3358 controls. Int J Cancer 104:650–657PubMedCrossRef
65.
Liu G, Zhou W, Christiani DC (2005) Molecular epidemiology of non-small cell lung cancer. Semin Respir Crit Care Med 26:265–272PubMedCrossRef
66.
Ahrendt SA, Decker PA, Alawi EA, Zhu Yr YR, Sanchez-Cespedes M, Yang SC, Haasler GB, Kajdacsy-Balla A, Demeure MJ, Sidransky D (2001) Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer 92:1525–1530PubMedCrossRef
67.
Johnson L, Mercer K, Greenbaum D, Bronson RT, Crowley D, Tuveson DA, Jacks T (2001) Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 410:1111–1116PubMedCrossRef
68.
Lubet RA, Zhang Z, Wiseman RW, You M (2000) Use of p53 transgenic mice in the development of cancer models for multiple purposes. Exp Lung Res 26:581–593PubMedCrossRef
69.
Sekido Y, Fong KW, Minna JD (1998) Progress in understanding the molecular pathogenesis of human lung cancer. Biochim Biophys Acta 1378:F21–F59PubMed
70.
Bode AM, Dong Z (2005) Signal transduction pathways in cancer development and as targets for cancer prevention. Prog Nucleic Acid Res Mol Biol 79:237–297PubMed
71.
Hecht SS (2003) Tobacco carcinogens, their biomarkers, and tobacco-induced cancer. Nature Rev Cancer 3:733–744CrossRef
72.
Schuller HM (2002) Mechanisms of smoking-related lung and pancreatic adenocarcinoma development. Nat Rev Cancer 2:455–463PubMedCrossRef
73.
West KA, Brognard J, Clark AS, Linnoila IR, Yang X, Swain SM, Harris C, Belinsky S, Dennis PA (2003) Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells. J Clin Invest 111:81–90PubMedCrossRef
74.
Heeschen C, Jang JJ, Weis M, Pathak A, Kaji S, Hu RS, Tsao PS, Johnson FL, Cooke JP (2001) Nicotine stimulates angiogenesis and promotes tumor growth and atherosclerosis. Nat Med 7:833–839PubMedCrossRef
75.
Moraitis D, Du B, De Lorenzo MS, Boyle JO, Weksler BB, Cohen EG, Carew JF, Altorki NK, Kopelovich L, Subbaramaiah K, Dannenberg AJ (2005) Levels of cyclooxygenase-2 are increased in the oral mucosa of smokers: evidence for the role of epidermal growth factor receptor and its ligands. Cancer Res 65:664–670PubMed
76.
Belinsky SA (2005) Silencing of genes by promoter hypermethylation: key event in rodent and human lung cancer. Carcinogenesis 26:1481–1487PubMedCrossRef
77.
World Health Organization (1997) Tobacco or health: a global status report. WHO, Geneva, pp 10–48
78.
Blot WJ, Fraumeni JF Jr (1996) Cancers of the lung and pleura. In: Schottenfeld D, Fraumeni J (eds) Cancer epidemiology and prevention. Oxford University Press, New York, pp 637–665
79.
American Cancer Society (2001) Cancer facts and figures 2001. American Cancer Society, Atlanta, GA, pp 29–32
Metadaten
Titel
Cigarette smoking: cancer risks, carcinogens, and mechanisms
verfasst von
Stephen S. Hecht
Publikationsdatum
01.11.2006
Verlag
Springer-Verlag
Erschienen in
Langenbeck's Archives of Surgery / Ausgabe 6/2006
Print ISSN: 1435-2443
Elektronische ISSN: 1435-2451
DOI
https://doi.org/10.1007/s00423-006-0111-z

Weitere Artikel der Ausgabe 6/2006

Langenbeck's Archives of Surgery 6/2006 Zur Ausgabe

Original Article

Targeting the EGF/VEGF-R system by tyrosine-kinase inhibitors—a novel antiproliferative/antiangiogenic strategy in thyroid cancer

Case Management and Clinical Consequences

Implantation of parathyroid carcinoma along fine needle aspiration track

Abstracts

25th Annual Meeting of the Surgical Working Group of Endocrine Surgery (CAEK) of the German Society of Visceral Surgery, 24–25 November 2006, Duisburg, Germany

Original Article

Metastases to the thyroid gland: seventeen cases operated on in a single clinical center

Current Concepts in Endocrine Surgery

Clinical outcome of different modes of resection in papillary thyroid carcinomas with laryngotracheal invasion

Original Article

Accuracy of intra-operative PTH measurement during subtotal parathyroidectomy for tertiary hyperparathyroidism after renal transplantation

Neu im Fachgebiet Chirurgie

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 Ablationstherapie Nachrichten

Nach der Katheterablation von Vorhofflimmern kommt es bei etwa einem Drittel der Patienten zu Rezidiven, meist binnen eines Jahres. Wie sich spätere Rückfälle auf die Erfolgschancen einer erneuten Ablation auswirken, haben Schweizer Kardiologen erforscht.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 Operationsvorbereitung Nachrichten

Derzeit wird empfohlen, eine Therapie mit GLP-1-Rezeptoragonisten präoperativ zu unterbrechen. Eine neue Studie nährt jedoch Zweifel an der Notwendigkeit der Maßnahme.

Ureterstriktur: Innovative OP-Technik bewährt sich

19.04.2024 EAU 2024 Kongressbericht

Die Ureterstriktur ist eine relativ seltene Komplikation, trotzdem bedarf sie einer differenzierten Versorgung. In komplexen Fällen wird dies durch die roboterassistierte OP-Technik gewährleistet. Erste Resultate ermutigen.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.
Bildnachweise